Al Abri Sulaiman Y, Burad Jyoti, Al Wahaibi Mazin M
Anesthesia and Intensive Care, Oman Medical Specialty Board, Muscat, OMN.
Anesthesia and Intensive Care, Sultan Qaboos University Hospital, Muscat, OMN.
Cureus. 2023 Jun 12;15(6):e40340. doi: 10.7759/cureus.40340. eCollection 2023 Jun.
Acute kidney injury (AKI) is associated with adverse outcomes in critically ill patients. Coronavirus disease 2019 (COVID-19) affects the renal system frequently and leads to AKI. This study aims to determine the incidence of AKI, risk factors including hyperglycemia, and the requirement for renal dialysis.
A retrospectively observational study was done at Sultan Qaboos University Hospital between March 2020 and September 2021. A total of 286 adult patients with laboratory-confirmed COVID-19 infection admitted to the intensive care unit (ICU) were included in the study. The patient's medical records were reviewed. Patients' baseline demographic characteristics, APACHE score on admission, clinical data including length of stay, oxygenation parameters, ventilator days, shock, AKI (KIDIGO guideline), dialysis, medications, lab on admission as well as during the ICU stay, and the outcome (mortality) were recorded in detail. Follow-up was done till discharge from ICU.
The study population included 68.5% (196/286) males. The median age was 56 years (interquartile range, IQR: 43-66.25). The incidence of AKI was 55.2% (158/286) overall. Out of those who had AKI, 27.2% (43/158), 31.6% (50/158), and 41.1% (65/158) developed AKI stages 1, 2, and 3, respectively. Univariate analysis for the development of AKI showed the following significant variables: age (p=0.005; odds ratio, OR 1.024; 95% confidence interval, CI 1.007-1.041), creatinine level on admission (p=0.012; OR 1.005; 95%CI 1.001-1.008), APACHE score on admission (p<0.001; OR 1.049; 95%CI 1.021-1.077), P/F ratio (p<0.001; OR 0.991; 95%CI 0.987-0.995), nephrotoxic agent (p<0.001; OR 8.556; 95%CI 4.733-15.467), shock (p<0.001; OR 8.690; 95%CI 5.087-14.843), days on the ventilator (p<0.001; OR 1.085; 95%CI 1.043-1.129), and length of stay in ICU (p<0.001; OR 1.082; 95%CI 1.047-1.119). The multivariate analysis confirmed only shock (p=0.004; OR 5.893; 95%CI 1.766-19.664). A total of 41.7% (66/158) of patients received dialysis. Hyperglycemia was not associated with the development of AKI. For patients with AKI, those having high APACHE score (p<0.001), shock (p=0.56; OR 2.326; 95%CI 1.036-5.223), ischemic heart disease (IHD) (p=0.002; OR 9.000; 95%CI 1.923-42.130), and hypertension (p=0.023; OR 2.145; 95%CI 11.125-4.090) were significantly associated with the requirement of dialysis. The mortality was found to be 59.1% (169/286) overall whereas it was 83.5% (132/158) for AKI versus 28.9% (37/158) for non-AKI cases.
A high incidence of AKI for critically ill COVID-19 cases was found in this study. The shock was the only significant predictor for the development of AKI. AKI is associated with high mortality in these patients.
急性肾损伤(AKI)与危重症患者的不良预后相关。2019冠状病毒病(COVID-19)常累及肾脏系统并导致AKI。本研究旨在确定AKI的发生率、包括高血糖在内的危险因素以及肾脏透析的需求。
2020年3月至2021年9月在苏丹卡布斯大学医院进行了一项回顾性观察研究。共有286例入住重症监护病房(ICU)且实验室确诊为COVID-19感染的成年患者纳入本研究。查阅了患者的病历。详细记录了患者的基线人口统计学特征、入院时的急性生理与慢性健康状况评分系统(APACHE)评分、临床数据(包括住院时间、氧合参数、机械通气天数、休克、AKI(按照改善全球肾脏病预后组织(KIDIGO)指南)、透析、用药情况)、入院时以及在ICU住院期间的实验室检查结果,以及结局(死亡率)。随访至患者从ICU出院。
研究人群中男性占68.5%(196/286)。中位年龄为56岁(四分位间距,IQR:43 - 66.25)。总体AKI发生率为55.2%(158/286)。在发生AKI的患者中,分别有27.2%(43/158)、31.6%(50/158)和41.1%(65/158)发展为1期、2期和3期AKI。AKI发生情况的单因素分析显示以下显著变量:年龄(p = 0.005;比值比,OR 1.024;95%置信区间,CI 1.007 - 1.041)、入院时肌酐水平(p = 0.012;OR 1.005;95%CI 1.001 - 1.008)、入院时APACHE评分(p < 0.001;OR 1.049;95%CI 1.021 - 1.077)、氧合指数(P/F)(p < 0.001;OR 0.991;95%CI 0.987 - 0.995)、肾毒性药物(p < 0.001;OR 8.556;95%CI 4.733 - 15.467)、休克(p < 0.001;OR 8.690;95%CI 5.087 - 14.843)、机械通气天数(p < 0.001;OR 1.085;95%CI 1.043 - 1.129)以及在ICU的住院时间(p < 0.001;OR 1.082;95%CI 1.047 - 1.119)。多因素分析仅证实休克(p = 0.004;OR 5.893;95%CI 1.766 - 19.664)。共有41.7%(66/158)的患者接受了透析。高血糖与AKI的发生无关。对于AKI患者,高APACHE评分(p < 0.001)、休克(p = 0.56;OR 2.326;95%CI 1.036 - 5.223)、缺血性心脏病(IHD)(p = 0.002;OR 9.000;95%CI 1.923 - 42.130)和高血压(p = 0.023;OR 2.145;95%CI 1.125 - 4.090)与透析需求显著相关。总体死亡率为59.1%(169/286),而AKI患者的死亡率为83. 5%(132/158),非AKI患者为28.9%(37/158)。
本研究发现危重症COVID - 19病例中AKI的发生率较高。休克是AKI发生的唯一显著预测因素。AKI与这些患者的高死亡率相关。